Sphera Funds Management LTD. Takes Position in Chemomab Therapeutics Ltd. (NASDAQ:CMMB)

Sphera Funds Management LTD. bought a new stake in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 0.08% of Chemomab Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Chemomab Therapeutics Stock Down 3.5 %

NASDAQ CMMB opened at $1.67 on Thursday. The stock has a market capitalization of $23.98 million, a P/E ratio of -1.65 and a beta of 0.66. Chemomab Therapeutics Ltd. has a 52-week low of $0.42 and a 52-week high of $2.55. The firm has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.36.

Analyst Ratings Changes

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $11.00 target price (down from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).